posted on 2023-04-03, 20:41authored byShyam M. Kavuri, Naveen Jain, Francesco Galimi, Francesca Cottino, Simonetta M. Leto, Giorgia Migliardi, Adam C. Searleman, Wei Shen, John Monsey, Livio Trusolino, Samuel A. Jacobs, Andrea Bertotti, Ron Bose
Supplementary Figure S1. Drug sensitivity of HER2 or KRAS mutations in soft agar colony formation assay. Supplementary Figure S2. NCI-H508 cell xenograft growth curves. Supplementary Figure S3. Neratinib sensitivity of KRAS WT and KRAS mutant colorectal cancer lines. Supplementary Figure S4. HER2 mutant PDX's are cetuximab resistant. Supplementary Figure S5. Immunohistochemistry on PDX M122. Supplementary Figure S6. Immunohistochemistry on PDX M051. Supplementary Figure S7. HER2 L866M is an activating mutation that confers cetuximab resistance. Supplementary Figure S8. HER2 S310F is more sensitive to trastuzumab than HER2 L866M.